SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (7648)3/1/2000 3:13:00 PM
From: Pseudo Biologist  Read Replies (1) of 9719
 
Novalon licenses:

From novalon.com

The Company currently has BioKey Assay collaborations with Bayer, Ares-Serono, Millennium and Novartis Research Foundation. Current collaborations are outlined below:

Bayer: The Company initiated a collaboration with Bayer in September 1998. The collaboration allowed for the identification of BioKeys and the development of BioKey assays for genomics targets in the anti-infective area. Novalon has successfully developed BioKey assays for all targets in the Bayer collaboration.
Millennium: The Company initiated a collaboration with Millennium in May 1998. The collaboration allowed for the identification of BioKeys and the development of BioKey assays for genomics targets supplied by Millennium.

Ares Serono: The Company initiated a three-year collaboration with Ares Serono in June 1999. The collaboration allowed for the identification of BioKeys and the development of BioKey assays for targets supplied by Ares Serono.

Novartis: The Company initiated its first agbio collaboration with the Novartis Research Foundation, in November 1999. The collaboration allowed for the identification of BioKeys and the development of BioKey assays for targets supplied by Novartis Agribusiness Biotechnology Research Inc. in the herbicide and fungicide area.

I believe they had something with Cubist too, could be wrong. This may be a nice IPO, too bad it will start its public life at >$1B.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News